SEC Company Response from enVVeno Medical (NVNO) — Dec 18, 2017

enVVeno Medical Corp
Date: Dec. 18, 2017 · CIK: 0001661053 · Accession: 0001493152-17-014691

View on Edgar

AI Filing Summary & Sentiment

File numbers found in text: 333-220372

Date

Dec. 18, 2017

Author

HANCOCK

Form

CORRESP

Company

enVVeno Medical Corp

Letter

VIA EDGAR Division of Corporation Finance Request for Acceleration Acceleration Request Request Date: December 19, 2017 Request Time: 4:30 p.m. Eastern Time (or as soon thereafter as practicable)

Dear Ms. Ravitz:

Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Hancock Jaffe Laboratories, Inc., a Delaware corporation (the “Registrant”), hereby respectfully requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form S-1 (File No. 333-220372), to become effective at 4:30 p.m. Eastern Time on December 19, 2017, or as soon thereafter as practicable, or at such later time as the Registrant or its counsel may orally request via telephone call to the staff of the Commission. The Registrant hereby authorizes K&L Gates LLP, counsel to the Company, to orally modify or withdraw this request for acceleration.

The Registrant requests that it be notified of such effectiveness by a telephone call to Michael A. Hedge at (949) 623-3519, or in his absence, Alexa M. Ekman at (949) 623-3603.

Sincerely,
HANCOCK
JAFFE LABORATORIES, INC.

Show Raw Text

CORRESP
1
filename1.htm

Hancock
Jaffe Laboratories, Inc.

70
Doppler

Irvine,
California 92618

December
18, 2017

VIA
EDGAR

U.S.
Securities and Exchange Commission

Division
of Corporation Finance

100
F Street, N.E.

Washington,
D.C. 20549

Attn:     Amanda
Ravitz

    Re:
    Hancock
    Jaffe Laboratories, Inc.

    Registration
    Statement on Form S-1

    File
    No. 333-220372

    Request
    for Acceleration

Acceleration
Request

Request
Date: December 19, 2017

Request
Time: 4:30 p.m. Eastern Time (or as soon thereafter as practicable)

Dear
Ms. Ravitz:

Pursuant
to Rule 461 promulgated under the Securities Act of 1933, as amended, Hancock Jaffe Laboratories, Inc., a Delaware corporation
(the “Registrant”), hereby respectfully requests that the Securities and Exchange Commission (the “Commission”)
take appropriate action to cause the above-referenced Registration Statement on Form S-1 (File No. 333-220372), to become effective
at 4:30 p.m. Eastern Time on December 19, 2017, or as soon thereafter as practicable, or at such later time as the Registrant
or its counsel may orally request via telephone call to the staff of the Commission. The Registrant hereby authorizes K&L
Gates LLP, counsel to the Company, to orally modify or withdraw this request for acceleration.

The
Registrant requests that it be notified of such effectiveness by a telephone call to Michael A. Hedge at (949) 623-3519, or in
his absence, Alexa M. Ekman at (949) 623-3603.

    Sincerely,

    HANCOCK
    JAFFE LABORATORIES, INC.

    By:

    /s/
    Steven A. Cantor

    Steven
    A. Cantor

    Co-Chief
    Executive Officer

    cc:

    Benedict
    Broennimann, M.D., Hancock Jaffe Laboratories, Inc.

    Bill
    Abbott, Hancock Jaffe Laboratories, Inc.

    Michael
    A. Hedge, K&L Gates LLP

SecProbe.io